21 results for "Alfred L. Garfall"
Showing 1–20 · 2.42 seconds · RSS
-
Journal Article
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after CAR-T therapies vary according to age, race, and ethnicity. We also review the…
-
Journal Article
4473 Immune control of plasma cell disorders – in-depth analysis of Sox2 immunity in MGUS
OBJECTIVES/GOALS: We aim to identify and characterize anti-Sox2-specific CD8+ T cell responses in stable MUGS patients expressing HLA class I alleles-A*02:01 and /or -B*07:02. METHODS/STUDY POPULATION: Cross sectional study of patients with stable MGUS defined as stable serum paraprotein for ≥ 12…
-
Journal Article
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
IntroductionBispecific antibodies (BsAbs) are novel immunotherapy agents for the treatment of relapsed/refractory multiple myeloma (RRMM). Currently, 3 BsAbs (teclistamab, talquetamab, and elranatamab) are approved for the treatment of RRMM. Administering BsAbs in different practice settings is…
-
Journal Article
Nontuberculous mycobacterial infections following teclistamab in multiple myeloma
Not available.
-
Journal Article
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted…
-
Journal Article
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice
Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is lacking. We show that busulfan-conditioned human IL-6–transgenic…
-
Journal Article
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and…
-
Journal Article Full text
Teclistamab in Relapsed or Refractory Multiple Myeloma
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients…
-
Journal Article
Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
Abstract: Chimeric antigen receptor T-cell (CART) therapy targeting B-cell maturation antigen (CART-BCMA) is a transformative treatment for multiple myeloma (MM). However, its high cost and the need for specialized centers may limit access for racial and ethnic minority populations (REMPs), who are…
-
Journal Article Full text
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
-
Journal Article
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was…
-
Journal Article
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Abstract Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT…
-
Journal Article
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Abstract Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers…